Corporate Finance Division
Medical Device & Pharmacuticals Venture Capital
Synergy Capital Markets is committed to helping exceptional entrepreneurs build the next generation of great Medical Device and Pharmaceutical companies. The firm partners with Medical Device and Pharmaceutical sector companies at all stages of development, with an emphasis on the discovery and development of novel therapeutics. SJM Capital has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building.
The United States remains the largest medical device market in the world with a market size of around $140 billion, and the U.S. market represented about 40 percent of the global medical device market in 2015. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2015.
The U.S. pharmaceutical market is the world’s most important national market. Together with Canada and Mexico, it represents the largest continental pharmaceuticals market worldwide. The United States alone holds over 45 percent of the global pharmaceutical market. In 2016, this share was valued around $446 billion U.S. dollars. Many of the global top companies are from the United States. In 2016, six out of the top 10 companies were from the United States when based on pure pharmaceutical revenue.
Fostering Growth without Diluting Equity:
For Medical Device & Pharmaceuticals companies at critical stages of development, debt can serve as a key financing option to foster growth, with minimal dilution of equity ownership. At Synergy Capital Markets, not only do we understand the industries of our portfolio Medical Device & Pharmaceuticals companies, but we also understand the growth process - and occasionally the growing pains - they undergo.
When venture debt is used appropriately, we believe entrepreneurs gain the following benefits:
Able to raise capital in a way that benefits the team and the business as a result of the greater flexibility offered by venture debt than traditional forms of debt financing
Have more time between equity rounds to build the business and achieve critical milestones, which creates potential for greater valuation
Retain a larger ownership stake in the company prior to an IPO or other liquidity event
Achieving milestones quickly in many cases also means reaching the IPO stage more rapidly